- Home
- DOMH vs MREO Comparison
DOMH vs MREO Comparison
Compare DOMH & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMH | MREO |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 50.3M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DOMH | MREO |
|---|---|---|
| Price | $1.74 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $1.97 |
| AVG Volume (30 Days) | 159.5K | ★ 1.1M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 50.40% | N/A |
| EPS Growth | ★ 34.03 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $1.85 | $0.20 |
| 52 Week High | $6.15 | $2.37 |
Technical Indicators
Market Signals| Indicator | DOMH | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 32.54 | 37.34 |
| Support Level | N/A | $0.27 |
| Resistance Level | $3.29 | $0.35 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.25 | 0.40 |
Price Performance
Historical ComparisonAbout DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).